A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for Wet Age-Related Macular Degeneration
A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Sponsor: Genaera Corporation
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Genaera Corporation
- Macular Degeneration · Phase PHASE2 · May 2007
- Macular Degeneration · Phase PHASE2 · Feb 2007
- Macular Degeneration · Phase PHASE2
More terminations from Genaera Corporation
Other Wet Age-Related Macular Degeneration trials with similar outcome
A PHASE3 clinical study on Wet Age-Related Macular Degeneration, this trial is terminated or withdrawn. The trial is conducted by Genaera Corporation and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Jun 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genaera Corporation
For direct contact, visit the study record on ClinicalTrials.gov .